Syntara Expands Scar Drug Trial to 30 Patients With Results Due Q1 2027 [VIDEO]
Syntara's SNT-9465 skin scarring study expansion to 30 participants — backed by validated patient selection data and a new Sydney clinical site — sets up a more robust Phase 1b readout expected in Q1 2027.
Key Takeaways
- Syntara has expanded its SNT-9465 Phase 1b study from 20 to 30 participants, with top-line results now expected in Q1 2027 and the double-blind design maintained throughout.
- Baseline biopsy data from five participants confirmed markedly higher LOX activity in scars under 24 months old, validating the trial's patient selection strategy before any efficacy data is unblinded.
- The Skin Hospital, Sydney has been added as a second clinical site to support timely completion of the expanded cohort.
- SATELLITE study data showed eight SNT-6302 participants discontinued due to local skin reactions, directly reinforcing the clinical rationale for advancing the improved second-generation compound SNT-9465.
- The cohort expansion was described by management as cost-effective at the current study stage, with no additional capital raise flagged to support the expanded program.
![FirstWave Cloud Technology Cuts FY26 Loss 80% With Second Year of Positive Cash Flow [VIDEO]](https://media.stockwirex.com/server-room-display.jpg)
![Genetic Signatures Agrees Merger With Microba to Build $30M Revenue Diagnostics Group [VIDEO]](https://media.stockwirex.com/GSS-Lab-Interior.jpg)
![Immuron Ltd Secures Exclusive US Distribution Rights for PROIBS in $4.16B Market [VIDEO]](https://media.stockwirex.com/IMC-Store-Display.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X Pty Ltd (CAR No. 001 322 642) is a Corporate Authorised Representative of ShareX Pty Ltd (AFSL No. 519872), regulated by the Australian Securities and Investments Commission (ASIC). StockWire X is authorised to provide general financial product advice in relation to basic deposit products, securities, and managed investment schemes.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer